# Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS

> **NCT02706899** · PHASE1,PHASE2 · TERMINATED · sponsor: **Seagen Inc.** · enrollment: 19 (actual)

## Conditions studied

- Myelodysplastic Syndrome

## Interventions

- **DRUG:** vadastuximab talirine
- **DRUG:** Azacitidine
- **DRUG:** Placebo (for 33A)

## Key facts

- **NCT ID:** NCT02706899
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-02
- **Primary completion:** 2017-11-06
- **Final completion:** 2017-11-06
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Sponsor decision based on portfolio prioritization
- **Last updated:** 2019-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02706899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02706899, "Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02706899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*